BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li R, Li D, Jia G, Li X, Sun G, Zuo C. Diagnostic Performance of Theranostic Radionuclides Used in Transarterial Radioembolization for Liver Cancer. Front Oncol 2020;10:551622. [PMID: 33569342 DOI: 10.3389/fonc.2020.551622] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Jokar N, Moradhaseli F, Ahmadzadehfar H, Jafari E, Nikeghbalian S, Rasekhi AR, Assadi M. Theranostic approach in liver cancer: an emerging paradigm to optimize personalized medicine. Clin Transl Imaging. [DOI: 10.1007/s40336-022-00525-5] [Reference Citation Analysis]
2 Talebi AS, Rajabi H, Watabe H. Role of nanoparticles in transarterial radioembolization with glass microspheres. Ann Nucl Med 2022. [PMID: 35199286 DOI: 10.1007/s12149-022-01727-7] [Reference Citation Analysis]
3 Zhou N, Guo X, Sun H, Yu B, Zhu H, Li N, Yang Z. The Value of 18F-FDG PET/CT and Abdominal PET/MRI as a One-Stop Protocol in Patients With Potentially Resectable Colorectal Liver Metastases. Front Oncol 2021;11:714948. [PMID: 34858808 DOI: 10.3389/fonc.2021.714948] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Filippi L, Braat AJ. Theragnostics in primary and secondary liver tumors: the need for a personalized approach. Q J Nucl Med Mol Imaging 2021;65:353-70. [PMID: 34881847 DOI: 10.23736/S1824-4785.21.03407-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Zhou N, Meng X, Zhang Y, Yu B, Yuan J, Yu J, Zhu H, Yang Z. Diagnostic Value of Delayed PET/MR in Liver Metastasis in Comparison With PET/CT. Front Oncol 2021;11:717687. [PMID: 34527587 DOI: 10.3389/fonc.2021.717687] [Cited by in F6Publishing: 1] [Reference Citation Analysis]